Abstract
The emergence of drug-resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID-19 pandemic. While de novo drug development is a time-consuming process, repurposing existing approved medications offers a more expedient approach. In our prior in silico screening of the DrugBank database, fidaxomicin emerged as a potential SARS-CoV-2 papain-like protease inhibitor. This study extends those findings by investigating fidaxomicin‘s antiviral properties in vitro. Our results support further exploration of fidaxomicin as a therapeutic candidate against SARS-CoV-2, given its promising in vitro antiviral activity and favorable safety profile.
Original language | English (US) |
---|---|
Article number | e202400091 |
Journal | ChemistryOpen |
Volume | 13 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2024 |
Keywords
- antiviral therapy
- drug repurposing
- fidaxomicin
- in vitro
- SARS-CoV-2 PLpro
ASJC Scopus subject areas
- General Chemistry